CTSG and type 1 diabetes mellitus: In addition, targeting MHC class II molecular proteins is a possible way to alleviate T1D, for example, by activating cathepsin G (CatG) to degrade MHC class I molecules to attenuate CD4+ T-cell activation in NOD mice and improve islet function (36–38).